» Articles » PMID: 15673736

Tetracycline-resistant Clinical Helicobacter Pylori Isolates with and Without Mutations in 16S RRNA-encoding Genes

Overview
Specialty Pharmacology
Date 2005 Jan 28
PMID 15673736
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Tetracycline-resistant Helicobacter pylori strains have been increasingly reported worldwide. However, only a small number of tetracycline-resistant strains have been studied with regard to possible mechanisms of resistance and those studies have focused on mutations in the tetracycline binding sites of 16S rRNA-encoding genes. We here report studies of 41 tetracycline-resistant H. pylori strains (tetracycline MICs, 4 to 32 microg/ml) from North America (n = 12) and from East Asia (n = 29). DNA sequence analyses of 16S rRNA-encoding genes revealed that 22 (54%) of the resistant isolates carried one of five different single-nucleotide substitutions (CGA, GGA, TGA, AGC, or AGT) at the putative tetracycline binding site (AGA(965-967)). Single-nucleotide substitutions were associated with reduced ribosomal binding and with slightly increased tetracycline MICs (1 to 2 microg/ml). The 19 tetracycline-resistant isolates with no detectable mutations in the tetracycline binding site had normal tetracycline-ribosome binding. All tetracycline-resistant isolates, including those with and those without mutations in the tetracycline binding site, showed decreased accumulation of tetracycline. These results suggest that tetracycline resistance is multifactorial, involving alterations both in ribosomal binding and in membrane permeability.

Citing Articles

Antibiotic Resistance of : Mechanisms and Clinical Implications.

Hasanuzzaman M, Bang C, Gong E J Korean Med Sci. 2024; 39(4):e44.

PMID: 38288543 PMC: 10825452. DOI: 10.3346/jkms.2024.39.e44.


Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.

Lin Y, Shao Y, Yan J, Ye G J Clin Lab Anal. 2023; 37(7):e24885.

PMID: 37088871 PMC: 10220298. DOI: 10.1002/jcla.24885.


Clinical Implication of Drug Resistance for Management.

Argueta E, Ho J, Elfanagely Y, DAgata E, Moss S Antibiotics (Basel). 2022; 11(12).

PMID: 36551341 PMC: 9774604. DOI: 10.3390/antibiotics11121684.


Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Ansari S, Yamaoka Y Clin Microbiol Rev. 2022; 35(3):e0025821.

PMID: 35404105 PMC: 9491184. DOI: 10.1128/cmr.00258-21.


Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Tshibangu-Kabamba E, Yamaoka Y Nat Rev Gastroenterol Hepatol. 2021; 18(9):613-629.

PMID: 34002081 DOI: 10.1038/s41575-021-00449-x.


References
1.
Mendonca S, Ecclissato C, Sartori M, Godoy A, Guerzoni R, Degger M . Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000; 5(2):79-83. DOI: 10.1046/j.1523-5378.2000.00011.x. View

2.
Nikaido H . Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 1994; 264(5157):382-8. DOI: 10.1126/science.8153625. View

3.
Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V . Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother. 1995; 36(1):129-36. DOI: 10.1093/jac/36.1.129. View

4.
Midolo P, Korman M, Turnidge J, Lambert J . Helicobacter pylori resistance to tetracycline. Lancet. 1996; 347(9009):1194-5. View

5.
Schnappinger D, Hillen W . Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol. 1996; 165(6):359-69. DOI: 10.1007/s002030050339. View